ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 131,700 shares, an increase of 18.4% from the September 15th total of 111,200 shares. Currently, 1.3% of the company’s stock are short sold. Based on an average daily volume of 74,600 shares, the days-to-cover ratio is presently 1.8 days.

Institutional Trading of ABVC BioPharma

A hedge fund recently bought a new stake in ABVC BioPharma stock. Chase Investment Counsel Corp bought a new position in ABVC BioPharma, Inc. (NASDAQ:ABVC) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 178,377 shares of the company’s stock, valued at approximately $233,000. Chase Investment Counsel Corp owned approximately 1.69% of ABVC BioPharma at the end of the most recent quarter. Institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Price Performance

Shares of ABVC BioPharma stock opened at $0.59 on Wednesday. ABVC BioPharma has a 1 year low of $0.41 and a 1 year high of $3.35. The firm has a market cap of $6.37 million, a price-to-earnings ratio of -0.26 and a beta of 0.81. The company has a 50-day moving average of $0.66 and a 200 day moving average of $0.85.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share for the quarter. ABVC BioPharma had a negative return on equity of 139.97% and a negative net margin of 8,363.97%. The business had revenue of $0.12 million during the quarter.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.